Evaluation of the UK Myeloma Research Alliance risk profile in transplant-ineligible multiple myeloma patients treated with novel agents.
The heterogeneity of multiple myeloma (MM) significantly impacts treatment outcomes. Myeloma risk profile (MRP), introduced by the UK Myeloma Research Alliance, is a novel prognostic model for patients with transplant-ineligible newly diagnosed MM (TIE-NDMM) utilizing easily available clinical parameters.
The heterogeneity of multiple myeloma (MM) significantly impacts treatment outcomes. Myeloma risk profile (MRP), introduced by the UK Myeloma Research Alliance, is a novel prognostic model for patients with transplant-ineligible newly diagnosed MM (TIE-NDMM) utilizing easily available clinical parameters.
What the study was
- Study design
- Cohort/Observational Study
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Br J Haematol
Why it surfaced
Matched watchlist topic 'Hematologic malignancies (AML, MDS, CLL, MPN, lymphoma)'. Study design: Cohort/Observational Study. Score: 8/10 (N:3, R:3, D:1, P:1).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.